|
Embargo fino alle 17 . 40 (ora del Belgio) - 22 febbraio 2010Seneffe - Belgio, 22 febbraio 2010, IBt Bebig (Reuters: IBTH . BR - Bloomberg: IBTB BB) ha annunciato oggi che in seguito all investimento iniziale di US$ 2 milioni - sotto forma di prestito subordinato - effettuato nel novembre 2009 da IBt Bebig nella società Core Oncology, Inc . , le due società hanno iniziato a discutere di una possibile fusione delle loro attività . L obiettivo delle discussioni è giungere a una conclusione entro la fine del primo semestre del 2010If these were not to be conclusive, then the US$ 2 million loan would be reimbursed to IBt Bebig at its maturity, i . e . June 30, 2010 . If the negotiations were to achieve a merger of the two groups, then the combined entity would result into a truly global World player in its market, highly focused and entirely dedicated to the treatment of cancer by Brachytherapy, and generating revenues well above EUR 45 million (or US$ 60 million) . Core Oncology and IBt Bebig are today perfectly complementary in terms of market coverage, as Core Oncology focuses on the North American market whilst IBt Bebig has no direct presence in the USA . "Advanced discussions have been underway for some time . They could very well materialize in a matter of a few weeks or a few months; but, also, possibly, never . It all very much depends on the mutually satisfactory negotiation of a number of elements . The outcome of which is still uncertain at this stage", commented Francois Blondel, Chief Executive Officer of IBt Bebig . "But considering that a mandatory takeover bid will start this week on all IBt securities, we strongly felt important for all our shareholders to understand the strategic objective pursued and to know where we stand with our discussions" . About Core OncologyCore Oncology was founded September 15, 2006 by the existing management of the brachytherapy business owned by Coloplast, formerly Mentor, for the sole purpose of enhancing the levels of service and continuing our pursuit of innovation within the field of Radiation Oncology . Our philosophy is to make our Customers and their trusted patients the focus of our business . Meeting their needs is our primary goal . This is how we derived our name Core Oncology, as our Customers and Patients are our center, our focus, our core . On June 8, 2007, Core Oncology completed its acquisition of Mills Biopharmaceuticals LLC, the recently acquired brachytherapy division of Coloplast . Prior to this, the brachytherapy division was owned by Mentor Corporation . Initially formed in 1997, Mentor s brachytherapy division entered the radiation oncology market as the first company to offer both iodine and palladium brachytherapy sources . Since then the division has developed and successfully launched numerous innovative delivery technologies and services, including the Isoloader® workstation, prescription loaded needle services and proprietary cartridge systems for the Mick® applicator . This division has maintained a track record of strong year-on-year growth in a highly competitive market space . The management team that has facilitated the growth and development of the brachytherapy division is the same team that now manages Core Oncology . This team has remained intact from the beginning of the business . We pride ourselves on the culture that we have established and the employee retention that has resulted . About IBt Bebig . . . Contributing to saving lives!The IBt Bebig group is a European based group, active in the Medical Device segment of the Health Care sector . The core business of the IBt Bebig group is the cancer treatment by radiation technology . Its specificity is the treatment of cancer by brachytherapy, a technique which consists of placing a sealed implant containing a minuscule quantity of a radioactive isotope in the body, on either a temporary or on a permanent basis . Depending on the application, the implant can take the shape of a plaque, a seed or a catheter . The precise positioning of the implant allows the cancer cells to be destroyed while sparing the healthy tissues and increasing the patient s quality of life . Today, the alternative brachytherapy procedures cover the non-invasive treatment of cancers of the prostate, neck, head and eye, as well as certain gynecological cancers . The IBt Bebig group employs over 150 people and has entities in Germany, France, United Kingdom, Spain, Italy and India . Its Head Office is located in Seneffe, Belgium and the company has been listed on the Euronext stock exchange since April 1997 (Reuters : IBTH . BR - Bloomberg : IBTB BB) . ContactPaul-Emmanuel GoethalsHead of Investor Relations & CommunicationTel: +32 . 64 . 520 . 808E-mail: ir@ibt-bebig . euInternet: www . ibt-bebig . euCopyright Hugin Questo comunicato é distribuito da Hugin . L emittente è l unico responsabile per il contenuto del comunicato . [CN#163474]
|
